NPIF – Maven Equity Finance, managed by Maven Capital Partners (Maven) and part of the Northern Powerhouse Investment Fund (NPIF) has invested GBP750,000 in Blueberry Therapeutics Limited (Blueberry), a drug discovery and development company focused on developing innovative nanomedicines for difficult to treat skin and nail infections. The funding
Curam, a UK-wide carer platform that has set out to use technology to positively disrupt the UK’s GBP38 billion social care sector, has launched of its Series A round of fundraising. Since its launch in 2018, Curam has raised GBP3.6 million from high net worth and angel investors, and has
Fertility Focus, manufacturers of the OvuCore and OvuSense Pro family of fertility monitoring solutions, with class II medical device classification and 510(k)FDA clearance – has launched OvuFirst, a completely unique patented sensor designed to measure skin temperature, providing women with an understanding of when to try and conceive naturally, and
Innovative Molecules, a German, Munich-based drug development company focused on developing next-generation treatments for Herpes simplex-induced diseases, has closed a EUR20 million Series A equity financing round led by LSP (Life Sciences Partners).
Iksuda Therapeutics (Iksuda), the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, today announced it has completed a USD47 million (circa GBP34 million) financing round, co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners, with the Company being advised by Ashfords
Exponent has reached an agreement to sell BBI Healthcare (BBIH) or the ‘Business’, an international provider of differentiated self-care products serving Women’s Health, Diabetes and Energy Management markets, from BBI Group to Venture Life Group plc (Venture Life), a specialist in developing, manufacturing and commercialising products for the international self-care
Babylon Holdings Limited (Babylon), a digital-first value-based care company, and Alkuri Global Acquisition Corp (Alkuri Global), a special purpose acquisition company, today announced that they have entered into a definitive merger agreement. Upon closing of the transaction, the combined company will operate as Babylon and plans to trade on Nasdaq
Antidote Technologies Limited (Antidote) has closed USD23.2 million in funding to expand its digital patient engagement programs and clinical trial recruitment services. The funding round was led by LBO France, a private equity firm committed to supporting the growth of digital health, both in transforming health systems and accelerating medical
BGF has broken the GBP100 million life sciences investment milestone, backing more than 30 businesses across the fields of diagnostics, medtech and digital health, as well as services, software and tools supporting therapeutic development. To support the organisation’s continued drive into the industry, BGF has now created a specialist advisory
The Kempen European Private Equity Fund, the private equity investment fund of Kempen Capital Management (Kempen), has acquired a direct interest in the German group of opticians and audiologists Ounda, which currently operates 65 branches across Germany and targets the high-end segment of the opticians’ and audiologists’ market. Ounda was
12 November, 2026 – 5:00 pm
12 November, 2026 – 8:00 am
12 February, 2026 – 8:00 am
12 February, 2026 – 5:00 pm
